Core Insights - Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on developing small molecule drugs for virology and immunology [1] - Jefferies analyst Akash Tewari set a price target of $20 for Enanta, indicating a potential upside of approximately 83.74% from the current price of $10.88 [1] - Enanta announced an upsized public offering of 6.5 million shares at $10.00 per share, expected to close on October 2, 2025, to raise capital for research and development [2] Stock Performance - Currently, ENTA is trading at $10.97, reflecting a decrease of approximately 8.35% with a price drop of $1 [3] - The stock has shown volatility, with intraday fluctuations between a low of $9.91 and a high of $11.83 [3] - Over the past year, ENTA has experienced a high of $15.34 and a low of $4.09, indicating significant price movement and investor interest [3] Market Activity - Enanta's market capitalization is approximately $234.5 million, with a trading volume of 2,459,054 shares, suggesting strong investor interest [4] - The recent public offering and the bullish price target from Jefferies have attracted attention from investors [4][5] - The additional capital from the stock offering could support Enanta's growth and innovation in the biotechnology sector [4]

At 7:20 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading hi ...

Core Viewpoint - Enanta Pharmaceuticals, Inc. has announced an upsized underwritten public offering of 6,500,000 shares at a price of $10.00 per share, with the offering expected to close on October 2, 2025, pending customary conditions [1]. Company Summary - Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on developing small molecule drugs for virology and immunology indications [1]. - The entire offering of shares is being made by Enanta Pharmaceuticals [1].

Sep 30, 2025 4:11 PM Eastern Daylight Time Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock Share WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intend ...

PresentationGood morning, and welcome to Enanta Pharmaceuticals Conference Call. [Operator Instructions] Please be advised that this call is being recorded. I would now like to turn the call over to Jennifer Viera, Head of Investor Relations. Please go ahead.Jennifer VieraExecutive Director of Investor Relations & Corporate Communications Thank you, operator, and thanks to everyone for joining us this morning. The news release announcing the top line results of our RSVHR study became available earlier this ...

PresentationGood morning, and welcome to Enanta Pharmaceuticals Conference Call. [Operator Instructions] Please be advised that this call is being recorded. I would now like to turn the call over to Jennifer Viera, Head of Investor Relations. Please go ahead.Jennifer VieraExecutive Director of Investor Relations & Corporate Communications Thank you, operator, and thanks to everyone for joining us this morning. The news release announcing the top line results of our RSVHR study became available earlier this ...

Group 1 - The article is authored by Terry Chrisomalis, who operates the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace [1] - The service offers a comprehensive analysis of various pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] - A two-week free trial is currently available for new subscribers, with a monthly subscription priced at $49 and an annual plan offering a 33.50% discount at $399 [1][2] Group 2 - The Biotech Analysis Central service includes live chat and a range of analysis and news reports aimed at assisting healthcare investors in making informed decisions [2] - The author has no current stock or derivative positions in any mentioned companies and does not plan to initiate any within the next 72 hours [3] - The article reflects the author's personal opinions and is not compensated by any company mentioned [3]

Enanta Pharmaceuticals (NASDAQ:ENTA) shares rose on Monday despite the company reporting it did not achieve the primary objective in a mid-stage trial for its antiviral drug, zelicapavir, which is aimed at treating respiratory syncytial virus infections. The stock is up ...

Enanta Pharmaceuticals Conference Call Summary Company Overview - **Company**: Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) - **Focus**: Development of antiviral treatments, particularly for respiratory syncytial virus (RSV) Key Points from the Conference Call Industry and Product Development - **RSVHR Study**: A Phase 2b study evaluating the efficacy and safety of Zelekapavir in adults with acute RSV infection at high risk of complications was discussed. The study showed positive top-line results, indicating a strong rationale for further clinical development of Zelekapavir [4][25]. - **Target Population**: The study focused on high-risk adult patients, including those aged 65 or older and individuals with chronic heart or lung diseases. The results are significant as they represent the first time an antiviral treatment for RSV has shown clinically meaningful benefits in this demographic [5][25]. Clinical Results - **Efficacy**: Zelekapavir demonstrated a 35% improvement in symptom resolution duration in the high-risk population, reducing the time from 19 days (placebo) to 12 days [18]. - **Hospitalization Rates**: The hospitalization rate was significantly lower in the Zelekapavir group (1.7%) compared to the placebo group (5%) [21]. - **Viral Load Reduction**: Zelekapavir showed a robust antiviral effect, with a 0.6 to 0.7 log drop in viral load at the end of treatment and a faster median time to undetectable viral load [22][24]. Safety Profile - **Adverse Events**: Treatment-emergent adverse events occurred at similar rates between Zelekapavir (22%-24%) and placebo. Serious adverse events were lower in the Zelekapavir group (2%) compared to placebo (6%) [17]. - **Overall Tolerance**: Zelekapavir exhibited a favorable safety profile, with no treatment discontinuations or deaths attributed to the drug [17]. Future Directions - **Phase 3 Trial**: The results support advancing Zelekapavir into a Phase 3 study, with multiple potential registrational endpoints identified, including time to complete resolution of symptoms and hospitalization rates [24][25]. - **Partnership Opportunities**: There is interest in RSV assets, as there are currently no approved therapeutics for high-risk populations. Enanta's pipeline is positioned as the most advanced in the industry [49]. Additional Insights - **Study Design**: The RSVHR study was a double-blinded, placebo-controlled trial involving 186 high-risk adults, with a focus on symptom resolution and patient-reported outcomes [10][11]. - **Mechanistic Expectations**: The HR3 subgroup (high-risk patients) was expected to outperform the broader population, which was confirmed by the results [28]. - **Regulatory Discussions**: Enanta plans to engage with regulators to discuss optimal endpoints and trial designs for the Phase 3 study [35]. Conclusion - Enanta Pharmaceuticals has made significant progress in developing Zelekapavir as a treatment for RSV, particularly in high-risk adult populations. The positive results from the Phase 2b study provide a strong foundation for advancing to Phase 3 trials, with a focus on addressing the unmet needs in RSV treatment.

Study Overview - The Phase 2b RSVHR study (n=186) aimed to demonstrate a clinically meaningful reduction in symptom duration of at least ~1 day in high-risk adults treated with Zelicapavir [12] - The study's primary objective was to assess the time to resolution of RSV lower respiratory tract disease (LRTD) symptoms [15] - The study randomized 186 adults with COPD, congestive heart failure, asthma, or age ≥65 [15] Efficacy Results - Zelicapavir resulted in faster complete symptom resolution across multiple RiiQTM measures [33] - In the HR3 population, Zelicapavir showed a 3-day faster time to complete resolution of LRTD symptoms, a 6.7-day faster time to complete resolution of all RSV symptoms, and a 7.2-day faster time to complete resolution of total RiiQ 29 parameters compared to placebo [34, 39] - The study showed a statistically significant 2-day faster symptom resolution by PGI-S compared to placebo in both the efficacy (p=0.0446) and HR3 populations (p=0.0465) [36, 38, 40] Safety and Additional Endpoints - The study exhibited a favorable safety profile, with adverse events (AEs) being similar between the Zelicapavir and placebo groups [29, 31] - The hospitalization rate was lower for patients treated with Zelicapavir: 1.7% (2/115) vs 5.0% (3/60) on placebo [42] - A greater proportion of patients treated with Zelicapavir had undetectable viral load at the end of treatment in the Efficacy Population: 23.5% (27/115) vs 10.0% (6/60) (p=0.0198) and in the HR3 Population: 23.9% (22/92) vs 10.0% (5/50) (p=0.0292) [43] - Zelicapavir showed a viral load decline of 0.7 log at the end of treatment in the HR3 population [44, 45]